Antidiabetic drugs including GLP-1 receptor agonists and DPP-4 inhibitors show potential as brain tumor treatments by targeting metabolic and inflammatory pathways that fuel tumor growth.
Multiple diabetes drugs show antitumor potentialGLP-1RAs, DPP-4 inhibitors, metformin, and TZDs all target metabolic pathways exploited by brain tumors, with GLP-1RAs offering the advantage of blood-brain barrier penetration
What the researchers found
The review synthesizes evidence showing that metabolic syndrome features (hyperglycemia, insulin resistance, oxidative stress, altered adipokines) promote brain tumor growth, proliferation, and treatment resistance. GLP-1 receptor agonists and DPP-4 inhibitors target both metabolic and inflammatory aspects of brain tumors. Metformin activates AMPK and inhibits mTOR to impair tumor proliferation. Thiazolidinediones can induce tumor cell apoptosis and synergize with other therapies. All these approaches represent potential drug repurposing strategies.
Why it matters
Brain tumors, particularly glioblastoma, have limited treatment options and extremely poor prognosis. If existing antidiabetic drugs — already proven safe for long-term use — can be repurposed as adjunctive brain tumor therapies, this could rapidly expand the treatment toolkit. The metabolic reprogramming that tumor cells undergo makes metabolic interventions a rational strategy, and drugs like GLP-1RAs that cross the blood-brain barrier are particularly relevant.
How the study worked
Narrative review examining evidence for metabolic connections between diabetes/metabolic syndrome and brain tumors, and evaluating preclinical and clinical evidence for antidiabetic drug efficacy against brain tumors.
What this study cannot tell us
This is a narrative review with most evidence from preclinical studies and observational data. No randomized clinical trials of GLP-1RAs or DPP-4 inhibitors specifically for brain tumors have been published. The mechanisms described are largely demonstrated in cell culture and animal models. Extrapolating from diabetes-related metabolic effects to antitumor efficacy is speculative. Different brain tumor types may respond very differently to metabolic interventions.
How to read the evidence
This is a narrative review synthesizing primarily preclinical evidence and mechanistic rationale. While the biological reasoning is sound, clinical evidence for antidiabetic drugs as brain tumor therapies is very limited.
When this study was published
Published in 2025, this review captures growing interest in metabolic approaches to cancer treatment and the expanding therapeutic potential of incretin-based drugs in oncology.
The bigger picture
The intersection of metabolism and cancer — oncometabolism — is a rapidly growing field. Brain tumors are particularly metabolically active, and the link between diabetes and brain tumor progression provides a rationale for metabolic intervention. GLP-1 receptor agonists are especially interesting because they can cross the blood-brain barrier (as demonstrated by their effects on appetite and neuroinflammation), potentially delivering antitumor metabolic effects directly to the brain. This adds brain tumors to the growing list of conditions beyond diabetes and obesity where GLP-1 drugs may prove beneficial.
Questions still open
- Which brain tumor subtypes are most likely to respond to GLP-1RA-based metabolic intervention?
- Could GLP-1RAs be combined with standard brain tumor treatments (temozolomide, radiation) for synergistic effects?
- Do diabetic patients on GLP-1 drugs have lower brain tumor incidence or better outcomes when they develop brain tumors?
Common questions
Could GLP-1 drugs like Ozempic help treat brain cancer?
How does diabetes affect brain tumor growth?
Read the original research
Metabolic imbalance and brain tumors: The interlinking metabolic pathways and therapeutic actions of antidiabetic drugs.
Pharmacological research, 215, 107719
Citation
Kim, Young-Kook; Song, Juhyun. (2025). Metabolic imbalance and brain tumors: The interlinking metabolic pathways and therapeutic actions of antidiabetic drugs.. Pharmacological research, 215, 107719. https://doi.org/10.1016/j.phrs.2025.107719